ES2548513T3 - Compuestos de 4-piperidinilo para uso como inhibidores de tankirasa - Google Patents

Compuestos de 4-piperidinilo para uso como inhibidores de tankirasa Download PDF

Info

Publication number
ES2548513T3
ES2548513T3 ES12742957.9T ES12742957T ES2548513T3 ES 2548513 T3 ES2548513 T3 ES 2548513T3 ES 12742957 T ES12742957 T ES 12742957T ES 2548513 T3 ES2548513 T3 ES 2548513T3
Authority
ES
Spain
Prior art keywords
piperidin
oxo
methoxy
benzoyl
pyrrolidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12742957.9T
Other languages
English (en)
Spanish (es)
Inventor
Christine Hiu-Tung Chen
Noel Chin CHIN
Lucian V. Dipietro
Jianme FAN
Mark G Palermo
Michael David SHULTZ
Bakary-Barry Toure
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2548513T3 publication Critical patent/ES2548513T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ES12742957.9T 2011-07-13 2012-07-13 Compuestos de 4-piperidinilo para uso como inhibidores de tankirasa Active ES2548513T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161507321P 2011-07-13 2011-07-13
US201161507321P 2011-07-13
PCT/IB2012/053613 WO2013008217A1 (en) 2011-07-13 2012-07-13 4 - piperidinyl compounds for use as tankyrase inhibitors

Publications (1)

Publication Number Publication Date
ES2548513T3 true ES2548513T3 (es) 2015-10-19

Family

ID=46604017

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12742957.9T Active ES2548513T3 (es) 2011-07-13 2012-07-13 Compuestos de 4-piperidinilo para uso como inhibidores de tankirasa

Country Status (21)

Country Link
US (2) USRE46942E1 (enExample)
EP (1) EP2731940B1 (enExample)
JP (1) JP5957077B2 (enExample)
KR (1) KR20140051944A (enExample)
CN (1) CN103797006B (enExample)
AP (1) AP2014007400A0 (enExample)
AU (1) AU2012282076A1 (enExample)
BR (1) BR112014000792A2 (enExample)
CA (1) CA2841932A1 (enExample)
CO (1) CO6880065A2 (enExample)
CR (1) CR20140071A (enExample)
DO (1) DOP2014000012A (enExample)
EA (1) EA201490272A1 (enExample)
ES (1) ES2548513T3 (enExample)
IL (1) IL230430A0 (enExample)
MA (1) MA35342B1 (enExample)
MX (1) MX2014000536A (enExample)
PH (1) PH12014500126A1 (enExample)
TN (1) TN2014000016A1 (enExample)
WO (1) WO2013008217A1 (enExample)
ZA (1) ZA201400374B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013012723A1 (en) * 2011-07-13 2013-01-24 Novartis Ag Novel 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors
WO2013132253A1 (en) 2012-03-07 2013-09-12 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
AU2014239542A1 (en) * 2013-03-15 2015-10-01 Araxes Pharma Llc Covalent inhibitors of KRas G12C
BR112016001928B1 (pt) * 2013-08-07 2022-07-19 Merck Patent Gmbh Derivados de piperidina ureia, seu uso, medicamentos, e kit
EP3044221B1 (en) 2013-09-11 2018-02-21 Institute of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
CN105793264B (zh) * 2014-03-10 2017-09-01 四川海思科制药有限公司 取代的二氢苯并呋喃‑哌啶‑甲酮衍生物、其制备及用途
US9809598B2 (en) 2014-05-07 2017-11-07 Merck Patent Gmbh Heterocyclyl-butanamide derivatives
WO2016006974A2 (en) * 2014-07-11 2016-01-14 St Pharm Co., Ltd. Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
KR101739003B1 (ko) 2014-07-11 2017-05-23 에스티팜 주식회사 신규한 트리아졸로피리미디논 또는 트리아졸로피리디논 유도체, 및 이들의 용도
KR20160007347A (ko) 2014-07-11 2016-01-20 에스티팜 주식회사 신규한 이미다조트리아지논 또는 이미다조피라지논 유도체, 및 이들의 용도
WO2016006975A2 (en) * 2014-07-11 2016-01-14 St Pharm Co., Ltd. Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
KR20180073681A (ko) 2015-11-02 2018-07-02 메르크 파텐트 게엠베하 1,4-디카르보닐-피페리딜 유도체
KR101777475B1 (ko) * 2015-12-08 2017-09-11 에스티팜 주식회사 신규한 디히드로피라노피리미디논 유도체 및 이들의 용도
JP7114076B2 (ja) 2015-12-22 2022-08-08 シャイ・セラピューティクス・エルエルシー がん及び炎症性疾患の処置のための化合物
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
CA3066939A1 (en) 2017-06-21 2018-12-27 SHY Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
CN113166097A (zh) 2018-12-03 2021-07-23 默克专利股份公司 作为端锚聚合酶抑制剂的4-杂芳基羰基-n-(苯基或杂芳基)哌啶-1-甲酰胺
JP7407461B2 (ja) 2018-12-19 2024-01-04 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ras病、及び線維性疾患の処置のためのrasスーパーファミリーと相互作用する化合物
AU2020328598A1 (en) 2019-08-15 2022-03-03 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds
WO2022146614A1 (en) * 2020-12-03 2022-07-07 Washington University Methods of treating and preventing kidney disease

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020022636A1 (en) 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
AU2004200A (en) 1999-01-14 2000-08-01 Meiji Seika Kaisha Ltd. Poly(adp-ribose) polymerase inhibitors consisting of pyrimidine derivatives
US6710058B2 (en) * 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
DE10056312A1 (de) 2000-11-14 2002-05-16 Bayer Ag Substituierte Amidoalkyluracile und ihre Verwendung
AUPR201600A0 (en) 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
EP1396488A1 (en) 2001-05-23 2004-03-10 Mitsubishi Pharma Corporation Fused heterocyclic compound and medicinal use thereof
ATE424388T1 (de) 2001-12-06 2009-03-15 Merck & Co Inc Mitotische kinesinhemmer
DE10201240A1 (de) 2002-01-15 2003-07-24 Bayer Ag Substituierte Alkyluracile und ihre Verwendung
AUPS019702A0 (en) 2002-01-29 2002-02-21 Fujisawa Pharmaceutical Co., Ltd. Condensed heterocyclic compounds
RU2292337C2 (ru) 2002-02-19 2007-01-27 Оно Фармасьютикал Ко., Лтд. Конденсированные производные пиридазина и лекарственные препараты, содержащие данные соединения в качестве активного ингредиента
AUPS137402A0 (en) 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
US7183287B2 (en) 2003-04-03 2007-02-27 Pharmacia Corporation Substituted pyrimidinones
DE602004022819D1 (de) 2003-06-06 2009-10-08 Vertex Pharma Von atp-bindende kassette transportern
NL1026826C2 (nl) 2003-08-13 2007-01-04 Pharmacia Corp Gesubstitueerde pyridinonen.
US7439254B2 (en) 2003-12-08 2008-10-21 Cytokinetics, Inc. Compounds, compositions, and methods
GB0405101D0 (en) * 2004-03-06 2004-04-07 Astrazeneca Ab Compounds
US7375102B2 (en) 2004-06-28 2008-05-20 Amgen Sf, Llc Tetrahydroquinazolin-4(3H)-one-related and tetrahydropyrido[2,3-D]pyrimidin-4(3H)-one-related compounds, compositions and methods for their use
MXPA06014933A (es) 2004-06-30 2007-02-28 Janssen Pharmaceutica Nv Derivados de 2-alquil quinazolinona sustituidos como inhibidores de poli(adp-ribosa) polimerasa-1.
US7888364B2 (en) 2004-09-02 2011-02-15 Curis, Inc. Pyridyl inhibitors of hedgehog signalling
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
MX2007016270A (es) 2005-06-27 2008-03-05 Amgen Inc Compuestos aril nitrilo anti-inflamatorios.
SI2021337T1 (sl) * 2006-04-25 2010-05-31 Lilly Co Eli Inhibitorji beta hidroksisteroidne dehidrogenaze
US8466150B2 (en) 2006-12-28 2013-06-18 Abbott Laboratories Inhibitors of poly(ADP-ribose)polymerase
CN101939006B (zh) 2007-09-12 2015-09-16 吉宁特有限公司 磷酸肌醇3-激酶抑制剂化合物与化疗剂的联合以及使用方法
US8354528B2 (en) 2007-10-25 2013-01-15 Genentech, Inc. Process for making thienopyrimidine compounds
US20100267626A1 (en) 2007-11-05 2010-10-21 Novartis Ag Methods and compositions for measuring wnt activation and for treating wnt-related cancers
KR101179753B1 (ko) 2007-11-06 2012-09-04 제일약품주식회사 신규한 트리시클릭 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 포함하는 약학조성물
JP2011507910A (ja) 2007-12-21 2011-03-10 ユニバーシティー オブ ロチェスター 真核生物の寿命を変更するための方法
US8889866B2 (en) 2008-03-27 2014-11-18 Janssen Pharmaceutica, Nv Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as PARP and tubulin polymerization inhibitors
WO2013012723A1 (en) * 2011-07-13 2013-01-24 Novartis Ag Novel 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors

Also Published As

Publication number Publication date
ZA201400374B (en) 2014-10-29
CA2841932A1 (en) 2013-01-17
JP2014522855A (ja) 2014-09-08
IL230430A0 (en) 2014-03-31
CO6880065A2 (es) 2014-02-28
AP2014007400A0 (en) 2014-01-31
NZ620426A (en) 2015-08-28
PH12014500126A1 (en) 2014-02-24
BR112014000792A2 (pt) 2017-10-31
DOP2014000012A (es) 2014-07-31
EP2731940B1 (en) 2015-08-19
JP5957077B2 (ja) 2016-07-27
WO2013008217A1 (en) 2013-01-17
EP2731940A1 (en) 2014-05-21
US20150126513A1 (en) 2015-05-07
EA201490272A1 (ru) 2014-05-30
CN103797006A (zh) 2014-05-14
TN2014000016A1 (en) 2015-07-01
CN103797006B (zh) 2016-01-27
MX2014000536A (es) 2014-12-05
MA35342B1 (fr) 2014-08-01
CR20140071A (es) 2014-10-16
US9163003B2 (en) 2015-10-20
USRE46942E1 (en) 2018-07-10
AU2012282076A1 (en) 2014-02-27
KR20140051944A (ko) 2014-05-02

Similar Documents

Publication Publication Date Title
ES2548513T3 (es) Compuestos de 4-piperidinilo para uso como inhibidores de tankirasa
EP2731942B1 (en) Novel 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors
AU2007311591B2 (en) Biaryl ether urea compounds
AU2009311756B2 (en) Modulators of amyloid beta.
EA032416B1 (ru) Соединения триазолопиримидина и их применения
JP2021515767A (ja) Erk5阻害剤の同定及び使用
UA109438C2 (uk) Азотні гетероциклічні сполуки, які застосовуються як інгібітори pde10
WO2005105814A1 (en) Tetracyclic inhibitors of janus kinases
WO2016102493A1 (en) Imidazopyridine ezh2 inhibitors
US9546173B2 (en) Substituted pyrrolo[3,4-d]pyrimidines as kinase inhibitors
NZ620426B2 (en) 4-piperidinyl compounds for use as tankyrase inhibitors
EP4536642A1 (en) Heterocyclic compounds as pi3ka inhibitors
NZ728416B2 (en) 2-(morpholin-4-yl)-1,7-naphthyridines
NZ728416A (en) 2-(morpholin-4-yl)-1,7-naphthyridines